Plunkett Research Online: Genelux Corp

GENELUX CORP (GNLX:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and other.....



Genelux Corp
Ticker: GNLX
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 805 267-9889
Fax:
Address: 2625 Townsgate Road
Suite 230
Westlake Village, CA 91361 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Biotechnology
Biotechnology
Healthcare

Ranks not available
Contacts Description
Thomas ZindrickCEO/Chairman of the Board/Director/President
Lourie ZakCFO/Chief Accounting Officer
See More
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and other.....See More See More

Auditor: Weinberg & Company
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2023202220212020
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
NameTitleSalary (US$)Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: